C-erbB-2 overexpression and survival in early onset breast cancer
C-erbB-2 overexpression and survival in early onset breast cancer
复制标题
DOI：
10.1023/a:1006498721508
复制
发表时间：
2000-09-01
影响因子：
3.8
通讯作者：
Wingren, S
中科院分区：
文献类型：
--
作者：
Agrup, M;Stäl, O;Wingren, S
年轻乳腺癌患者的生存率较低，并且已经证明年轻是不良预后的独立预测因子。c-erbB-2蛋白（也称为HER-2/neu）的过表达已被证明是乳腺癌的预后指标，特别是在腋窝淋巴结转移患者中。本研究旨在确定c-erbB-2蛋白过表达在早发性乳腺癌中的预后意义。对110例诊断时年龄小于或等于36岁的年轻乳腺癌患者进行c-erbB-2蛋白免疫组化染色分析。30例患者（27%）发现c-erbB-2蛋白过表达。当所有患者纳入分析（P = 0.002）和腋窝淋巴结转移患者（P = 0.0007）时，C-erbB-2阳性与不良生存率显著相关。在淋巴结阴性患者中没有发现这种关联。此外，当将淋巴结阳性患者分为接受或未接受辅助化疗的组时，与c-erbB-2相关的预后差异仍然存在。研究表明，c-erbB-2蛋白过表达是年轻乳腺癌腋窝淋巴结转移患者预后的重要因素。此外，无论患者是否接受辅助化疗，均观察到淋巴结阳性患者c-erbB-2过表达的不良预后。
Young breast cancer patients have a decreased survival rate and it has been demonstrated that young age is an independent predictor of adverse prognosis. Overexpression of c-erbB-2 protein (also known as HER-2/neu) has been shown to be a prognostic indicator in breast cancer in general and especially among patients with axillary nodal metastases. The present study was initiated to determine the prognostic significance of c-erbB-2 protein overexpression in early onset breast cancer.A population consisting of 110 young breast cancer patients, less than or equal to 36-year-old at diagnosis, was analyzed with immunohistochemical staining for c-erbB-2 protein.Thirty patients (27%) were found to overexpress the c-erbB-2 protein. C-erbB-2 positivity was significantly associated with poor survival when all patients were included in the analysis (P = 0.002) and for patients with axillary nodal metastases (P = 0.0007). No such association was found for node-negative patients. Furthermore, the difference in prognosis in relation to c-erbB-2 among node-positive patients was maintained, when these were stratified in groups treated or not treated with adjuvant chemotherapy.The study indicates that overexpression of c-erbB-2 protein is a strong prognostic factor in young breast cancer patients with axillary nodal metastases. Moreover, the adverse prognosis associated with c-erbB-2 overexpression in node-positive patients was observed whether or not the patients had received adjuvant chemotherapy.